IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

SARTORE BIANCHI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.973
AS - Asia 16.086
NA - Nord America 13.562
SA - Sud America 1.249
AF - Africa 334
OC - Oceania 227
Continente sconosciuto - Info sul continente non disponibili 20
Totale 51.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.809
DE - Germania 7.807
CN - Cina 6.759
IT - Italia 3.531
GB - Regno Unito 3.172
SG - Singapore 3.122
HK - Hong Kong 1.163
BR - Brasile 911
BD - Bangladesh 909
VN - Vietnam 850
IN - India 836
RU - Federazione Russa 797
FR - Francia 726
JP - Giappone 712
SE - Svezia 593
CH - Svizzera 572
CA - Canada 547
FI - Finlandia 454
ES - Italia 447
NL - Olanda 379
IE - Irlanda 366
KR - Corea 353
ID - Indonesia 254
TR - Turchia 231
TW - Taiwan 208
AU - Australia 199
PL - Polonia 148
DK - Danimarca 137
AT - Austria 127
RO - Romania 125
AR - Argentina 119
MX - Messico 119
BE - Belgio 96
IR - Iran 94
GR - Grecia 87
UA - Ucraina 78
CI - Costa d'Avorio 76
PT - Portogallo 71
IQ - Iraq 69
PH - Filippine 65
TH - Thailandia 65
CO - Colombia 64
SA - Arabia Saudita 60
NO - Norvegia 58
ZA - Sudafrica 50
IL - Israele 49
MA - Marocco 44
MY - Malesia 43
PK - Pakistan 43
CZ - Repubblica Ceca 42
JO - Giordania 42
EC - Ecuador 40
EG - Egitto 39
CL - Cile 38
HU - Ungheria 37
NZ - Nuova Zelanda 28
UZ - Uzbekistan 28
TN - Tunisia 25
DZ - Algeria 22
PE - Perù 22
VE - Venezuela 17
KE - Kenya 16
SK - Slovacchia (Repubblica Slovacca) 16
JM - Giamaica 14
KZ - Kazakistan 14
SC - Seychelles 14
LB - Libano 13
PY - Paraguay 13
AE - Emirati Arabi Uniti 12
HR - Croazia 12
AM - Armenia 11
BO - Bolivia 11
CR - Costa Rica 11
CY - Cipro 11
HN - Honduras 11
LT - Lituania 11
LU - Lussemburgo 11
RS - Serbia 11
UY - Uruguay 11
NP - Nepal 10
OM - Oman 10
GT - Guatemala 9
TT - Trinidad e Tobago 9
BG - Bulgaria 8
EU - Europa 8
SI - Slovenia 8
AL - Albania 7
EE - Estonia 7
GE - Georgia 7
SD - Sudan 7
AZ - Azerbaigian 6
ET - Etiopia 6
GN - Guinea 6
NG - Nigeria 6
AP - ???statistics.table.value.countryCode.AP??? 5
BB - Barbados 5
MK - Macedonia 5
MT - Malta 5
NI - Nicaragua 5
PA - Panama 5
Totale 51.341
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 7.001
Southend 2.261
Singapore 1.689
Ashburn 1.361
Hangzhou 1.070
Milan 1.010
Beijing 941
Hong Kong 886
Chandler 719
San Jose 634
Fairfield 536
Council Bluffs 520
Zurich 477
Shanghai 470
Dallas 466
Seattle 403
Houston 385
Wilmington 382
Los Angeles 370
New York 366
Redwood City 365
Dublin 348
Guangzhou 342
Helsinki 322
Princeton 322
Santa Clara 290
Hefei 287
Woodbridge 259
Nanjing 255
Cambridge 253
Ho Chi Minh City 252
Tokyo 248
Rome 246
Bengaluru 238
Hanoi 201
Lauterbourg 190
Jakarta 187
Ann Arbor 175
Buffalo 169
Dearborn 169
Ottawa 156
Boardman 148
Moscow 148
Turin 130
Des Moines 126
Toronto 124
Phoenix 122
Jinan 120
Istanbul 116
Munich 114
London 109
Seoul 102
Tianjin 101
Taipei 99
Chicago 98
São Paulo 95
Barcelona 93
Shenyang 91
Changsha 89
Naples 88
Madrid 87
The Dalles 87
Wuhan 85
Chengdu 84
Berlin 80
Columbus 78
Abidjan 76
Shenzhen 73
Amsterdam 69
Central District 69
Nuremberg 66
Boston 65
San Diego 62
Bologna 60
Hyderabad 60
Atlanta 59
Torino 59
Montreal 57
Cangzhou 55
Fuzhou 54
Vienna 54
Zhengzhou 52
Chennai 51
Hebei 51
Pune 51
Manchester 50
Mumbai 50
Warsaw 50
Brussels 49
Haiphong 47
Washington 44
Nanchang 43
Brooklyn 42
Dong Ket 42
Redmond 42
Central 41
Falls Church 40
San Francisco 40
Florence 39
Paris 39
Totale 31.636
Salva come PNG Salva come JPEG
Nome #
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 3.527
Liquid biopsy for rectal cancer: a systematic review 1.717
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 1.257
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 1.105
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy 860
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 813
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 703
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 690
Early-onset colorectal cancer in young individuals 679
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 638
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation 616
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 604
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies 571
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) 553
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer 548
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy 483
Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy 478
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 439
Third- or Later-line Therapy for Metastatic Colorectal Cancer : Reviewing Best Practice 432
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression 419
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 418
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 416
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 406
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion 405
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 395
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer 395
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 392
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib 338
Challenging chemoresistant metastatic colorectal cancer: Therapeutic strategies from the clinic and from the laboratory 338
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience 325
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 317
The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer 316
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 302
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 301
Strategies to tackle RAS-mutated metastatic colorectal cancer 297
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis 294
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 292
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 290
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 290
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 289
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma 287
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer 281
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ 277
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 277
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial 275
Detection of circulating tumor DNA in early- and late-stage human malignancies 274
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 273
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment 273
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 267
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab 266
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 261
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 260
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 260
Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review 258
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review 256
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA 256
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 255
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review 247
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial 247
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial) 246
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 245
Circulating tumor DNA to drive treatment in metastatic colorectal cancer 243
Adaptive mutability of colorectal cancers in response to targeted therapies 241
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series 240
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer 238
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study 233
Central Nervous System as Possible Site of Relapse in ERBB2-PositiveMetastatic Colorectal Cancer:Long-term Results of TreatmentWith Trastuzumab and Lapatinib 233
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab 229
TRKA expression and NTRK1 gene copy number across solid tumours 228
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer 228
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature 228
Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 227
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features 226
The genomic landscape of response to EGFR blockade in colorectal cancer 226
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer 225
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report 222
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review 221
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 220
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast 220
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 219
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types 219
The evolutionary landscape of treatment for BRAFv600e mutant metastatic colorectal cancer 218
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer 217
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases 216
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer 215
The right chance for temozolomide in metastatic colorectal cancer? 214
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 212
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 212
Oxaliplatin retreatment in metastatic colorectal cancer : systematic review and future research opportunities 212
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy : A pre-specified secondary analysis of the Valentino study 211
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity 208
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer 207
Personalized therapeutic strategies in HER2-driven gastric cancer 206
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers 205
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 205
Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases 204
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies 203
Is codon 13 KRAS mutation biologically different from codon 12 mutation 202
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 202
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer 200
Totale 38.024
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.184
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.184
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 0 0 0 0 0 0 262
2021/20223.659 338 254 271 324 322 197 280 258 391 291 241 492
2022/20233.904 405 337 283 371 315 628 201 285 414 115 332 218
2023/20248.336 252 321 329 364 617 368 1.163 1.061 541 1.006 1.130 1.184
2024/20258.873 1.077 1.037 906 892 431 414 444 728 464 613 654 1.213
2025/202614.961 1.312 932 1.608 1.225 1.244 957 1.709 692 1.461 1.055 1.929 837
Totale 53.023